Introduction
Heart failure with preserved ejection fraction (HFpEF) remains a complex syndrome with several phenotypes. [1] [2] [3] When a patient presents with signs and/or symptoms of heart failure, it has been hard to identify echocardiographic measures to disease severity. 4 The 2016 heart failure association HFA/ESC guidelines define HFpEF as an association of typical signs and symptoms of heart failure, normal LVEF and LV volumes and the presence of relevant structural heart disease (LV hypertrophy/LA enlargement) and/or diastolic dysfunction. 5 Nevertheless, high estimated pulmonary pressures have been also, reported but not underscored in guidelines. 5, 6 Both TOPCAT and I-PRESERVE, demonstrated that not all patients experience LA enlargement or an increase in pulmonary pressure r an increase in LV-mass. 4 To the best of our knowledge, the prognostic impact of the combination of left heart overload with right heart increase in afterload has not previously been described. We previously reported that E/e' was the only independent echocardiographic prognostic marker in patients included in the prospective KaRen observational study. 7 In the current study, we sought to define echocardiographic phenotypes (or at least one phenotype) that are easy to define. We aimed to define groups that have different prognosis. If so, it could be a starting point for suggesting treatments according to phenotypes instead of treatments that are the same for each phenotype of HFpEF syndrome.
Methods
The design of the KaRen study has previously been published. 8 The primary echocardiographic characteristics have also previously been reported. 9 The KaRen study included patients with HF symptoms who were seeking medical attention in the emergency ward. The following inclusion criteria were used: (1) acute presentation to the hospital with clinical signs and symptoms of HF, according to the Framingham criteria; (2) BNP> 100 pg/mL or NT-proBNP > 300 pg/mL; and (3) LVEF > 45% by echocardiography within the first 72 h. The measurements were performed according to previously established guidelines. 5, 10 All three inclusion criteria were verified within 72-h of presentation. Enrolment occurred during the initial visit, provided that any exclusion criteria had been ruled out. Information concerning the clinical history, comorbidities, clinical signs and symptoms, standard biology and treatments was prospectively collected during a scheduled hospital visit at 4-8 weeks after initiating treatment for acute heart failure.
Echocardiographic methods and definitions
All patients were followed and reassessed during a visit scheduled 4-8 weeks after the acute visit including an extensive echocardiographic assessment.
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Doppler echocardiography was performed using a ViVid 7 echo-platform (GE VingMed, Horten, Norway). The acquisitions were standardized to images of the left and right heart. Thereafter, all examinations were analysed at the core lab in Rennes. Each measurement was performed three times and averaged. The echocardiography reader was blinded to the clinical history of any patient. 9 This KaRen sub-study only included patients for whom the TR and LA volumes were recorded at the 4-to 8-week visit according to the EACVI/ASE recommendations. 12 The distribution of the maximal velocity of the tricuspid regurgitation measured by continuous Doppler (TR), was classified as low (<2.8 m/s), medium (2.8-3.1) or high (>3.1). The LA indexed volume was also classified as low (<34 mL/m (4) any other combinations. Analysis of LV longitudinal deformations was conducted for each patient using the loops from the apical 4-, 3-and 2-chamber views. According to the regional thickness of each segment the region of interest was adapted to systematically include the endocardial and the epicardial borders. The regional adaptation of the size of the region of interest was possible on the EchoPAC version we were using (EchoPAC B13, GE Healthcare, Horten, Norway). The same approach was used for the right ventricular focusing on the free wall in apical 4-chamber view.
Follow-up
Patients were included between May 2007 and December 2011 and followed prospectively from the initial hospitalization until November 2012. Vital status was assessed by clinical visit, telephone contact, or in Sweden by the Swedish National Patient Register and Population Register. The primary outcome was defined as time to mortality from any cause or first hospitalization due to HF. The secondary outcome was time to mortality from any cause. 8 
Study endpoints
The primary outcome was all-cause death and/or hospitalization for heart failure (HF). Hospitalization for HF was defined as admission to the hospital for any length of time, including daycare, with either HF treatment or HF as the primary reason for admission. All-cause mortality was the secondary outcome measure. Because this parameter was measured from the 4-to 8-week visit, the index date and start of follow-up were defined as the date of the 4-to 8-week visit and data collection.
Statistics
For descriptive purposes, the data are reported as the means ± standard deviation or median, 25th and 75th percentiles for continuous variables and follow-up times, respectively, and the number and percentage of non-missing values were used for categorical variables. Comparisons across the four classes of TR and LAVI levels were conducted using ANOVA for continuous variables and the chi-square test for categorical variables.
Kaplan-Meier analysis and log-rank statistics were used to compare the survival and event-free survival based on the combined levels of TR and LAVI. Adjustments for multiple comparisons for the log-rank test were conducted using the Sidak P-value. To estimate the hazard ratios and adjust for pertinent covariates, we used Cox proportional hazards modelling. The assumption of linearity was evaluated for continuous parameters using a graphical (Martingale residuals analysis) approach. The proportional hazard assumption was also assessed using a graphical (Schoenfeld residuals analysis) approach. For all statistical analyses, SAS version 9.4 (SAS Institute, Cary, NC, USA) was used.
Results
The overall KaRen population has previously been described. 13 
Description of the subgroups
In this study, a total of 237 patients (105 women), were analysed. The overall mean age was 76 ± 9 years. The mean LVEF was 62 ± 7%, E/e': 12.9 ± 6.0, left atrial volume index (LAVI): 48.1 ± 15.9 ml/m 2 , TR: 2.9 ± 0.9 m/s. Table 1 is summarizing the clinical characteristics these patients and according to four groups defined by LAVI and TR and Table 2 the echocardiographic characteristics. The most impaired group 2 with both high LAVI and high estimated TR comprised 57 older patients (24% of the whole population). Not surprisingly, these patients had higher values of natriuretic peptides, significantly less frequently were treated with statins, but more often treated with loop diuretics, beta-blockers or ACE-inhibitors. Moreover, these patients also had higher E/e 0 and larger right atrial size. The degree of LV hypertrophy was highest as well as the prevalence of significant mitral regurgitation.
Pronostic data Figure 1 shows the Kaplan-Meir curve for event-free survival according to combinations of indexed LA volumes (LAVI) and TR. The subgroup of patients showing both elevated TR and enlarged LA had a significantly worse prognosis than did the other subgroups. Figure 2 underscores this observation, displaying the differences in the risk of death observed during the follow-up in different echocardiographic groups. Figure 3 underscores the relevance of GLS (global longitudinal strain). A GLS < j-16j% was associated with a significant risk of death or hospitalization for heart failure but not for death only.
The combined prognostic value of enlarged LA (LAVI > 40 ml/m 2 ) with high estimated pulmonary pressure (TR >3.1 m/s) remained after adjusting for age, gender and co-morbidities. Table 3 displays the difference in survival according to the primary endpoint (Table 3A ) and the secondary endpoint (Table 3B ) and crude or after adjusting for the main clinical characteristics of HFpEF patients: it demonstrates that the association of enlarged LA and elevated pulmonary pressure was significantly, and was the only association, associated with the prognosis. 
LV-mass impact on the adjustment is displayed independently of the other parameters considered for the adjustment).

Discussion
In the present study, 24% of our HFpEF patients had combination of a TR > 3.1 m/s and an LAVI > 40 ml/m 2 and that was associated with a significantly worse prognosis.
HFpEF: a syndrome with a range of prognoses
The wide heterogeneity of clinical expression and outcomes in patients diagnosed with HFpEF has previously been reported. 2 Shah et al. proposed three clinical phenotypes: exercise-induced diastolic dysfunction, chronic volume overload, and associated RV failure with pulmonary hypertension. 14 The same authors examined a large cohort by using a pheno-mapping approach. 15 This approach involved the integration of big-data in the field of the HFpEF, and provided new interesting perspectives. Some clinical markers were also identified in KaRen. 7 . In addition, by using a more conventional approach, these authors used data from recent trials, such as TOPCAT, to describe the echocardiographic characteristics of the examined patients. 16 These patients were not all the same, even when the inclusion criteria were clearly defined. Shah also observed moderate or severe LA enlargement in 34% of the participants, according to TOPCAT. [16] [17] [18] The TR jet was > _3.5 m/s in 8% of the entire cohort.
Moreover, the combination of diastolic dysfunction criteria was associated with an exponential increase in the risk of clinical events during follow-up. The approach used in the present study was slightly different. The pulmonary hypertension observed in HFpEF was primarily type II (secondary to an increase in LA pressure). 19 Thus, we focused the aim of the study on demonstrating that a phenotype combining increased LA-size and increased estimated pulmonary pressure defines a sub-population requiring dedicated attention. This phenotype was frequently observed (24%) and associated with a significantly worse prognosis. Of note, longitudinal strain (GLS), parameter of LV systolic function that has already been proposed is demonstrated to be a relevant parameter for characterizing HFpEF.
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Importance of the LA
In 2007, Paulus et al. suggested that the size of the LA was not a key parameter to consider. 22 Since 2012, ESC-guidelines proposed that LA size and increased LV mass are required parameters for defining 'structural cardiac abnormality'. 5, 10 Since then, it has become crucial to measure the indexed LA volumes in patients with suspected HFpEF. The new EACVI/ASE recommendations underscore even more the importance of the indexed LA volume. 23 In 'normal LV-ejection fraction', average E/e 0 > 14, septal e 0 velocity < 7 cm/s or Lateral e 0 velocity <10 cm/, TR > 2.8 m/s and LA-volume index >34 ml/m 2 are key parameters for a diagnosis of LV diastolic dysfunction. Thus, the new recommendations are consistent with the observations of the present study in HFpEF patients in terms of both diagnosis and prognosis. Furthermore, in the present study, we highlighted the significantly worse prognosis of patients presenting chronic diastolic dysfunction (LA enlargement) with right heart consequences (combination of TR > 3.1 m/s and LAVI > 40 ml/m 2 ). That is an important combination to look for in HFpEF-patients and these patients are probably requiring a dedicated attention (considering their worse prognosis and their risk of re-hospitalization). These are also atrial fibrillation patients and so this specific high risk phenotype of HFpEf might require a dedicated attention to define the best treatment strategy taking into account its characteristics.
Limitations
This study involved the assessment of HFpEF patients at 4 to 8 weeks after receiving treatment for an episode of acute heart failure with a diagnosis of HFpEF, as defined in 2008. 8 The cut-off used to define the subgroups was based on the guidelines and was not calculated from the observed data for the cohort in the KaRen study. 5, 12 Our study finally focused on a single phenotype (large LA and increase estimated pulmonary pressure). The other groups will have to be explored in more details for defining specific phenotypes according to imaging but also clinical characteristics. In the present study, we did not focus on LV-mass but reported its impact on the multivariable model. Additive work on that key structural abnormality observed in HFpEF will have to be conducted in comparison to LAvolume (the second one stipulated in guidelines). 5 In 2007 (but also and 2014), LAVI and TR and their combination were not suggested as important HFpEF markers 1, 22 ; therefore, the patients in the present study were recruited according to a definition that might be criticized and revised according to more recent studies, study designs and recommendations. Only four patients had a LVEF <50%, it was thus impossible to look for differences according to the recently proposed cut-offs for defining HFpEF and heart failure with mildly reduced LVEF. 5 
Conclusions
In patients suffering from HFpEF, the combination of enlarged LA and elevated estimated pulmonary pressure has a strong prognostic impact that defines a specific high-risk phenotype of HFpEF.
